Resveratrol Attenuates Monocrotaline-Induced Pulmonary Hypertension in Rats.
10.4070/kcj.2006.36.10.683
- Author:
Dong Seok LEE
1
;
Jae Yeul JUNG
;
Yong Wook JUNG
Author Information
1. Department of Pediatrics, Dongguk University College of Medicine, Gyeongju, Korea. lds117@dongguk.ac.kr
- Publication Type:Original Article
- Keywords:
Resveratrol;
Vascular endothelial growth factor;
Endothelial nitric oxide synthase;
Pulmonary hypertension
- MeSH:
Animals;
Arterioles;
Blotting, Western;
Cardiovascular Diseases;
Hypertension, Pulmonary*;
Monocrotaline;
Nitric Oxide Synthase Type II;
Nitric Oxide Synthase Type III;
Rats*;
Rats, Sprague-Dawley;
Up-Regulation;
Vascular Endothelial Growth Factor A
- From:Korean Circulation Journal
2006;36(10):683-687
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND AND OBJECTIVES : Resveratrol (RVT) is a polyphenolic phytoalexin, and it has been demonstrated to be capable of protecting against cardiovascular disease. The aim of this study was to identify whether RVT might protect against monocrotaline (MCT)-induced pulmonary hypertension and whether vascular endothelial growth factor (VEGF), endothelial nitric oxide synthase (eNOS), and inducible nitric oxide synthase (iNOS) are involved in the beneficial effects. MATERIALS AND METHODS : Thirty Sprague Dawley rats were divided into three groups: the control (n=6), the MCT (n=12) and the MCT with RVT (5 mg/kg/day, n=12) groups. After 28 days, the tissue samples were obtained for morphometric analysis and Western blotting. RESULTS : In the MCT group, the right ventricle/(left ventricle+septum) weight ratio was significantly increased compared with that of the control group (0.51+/-0.07 vs. 0.20+/-0.03, p<0.01), which was markedly suppressed in the RVT treated group (0.35+/-0.08, p<0.01). Histological analysis also showed that MCT treatment increased the medial wall thickness of the pulmonary arterioles compared with that of the control group (36+/-8% vs. 17+/-5%, p<0.01), which also was significantly suppressed in the RVT treated group (27+/-5%, p<0.01). In addition, Western blot demonstrated the decreased expression of VEGF in the MCT group (p<0.01), which was upregulated after long term RVT treatment (p<0.01). The expression of eNOS was increased after MCT treatment (p<0.01), but upregulation of eNOS could not be reversed by the RVT treatment. The expression of iNOS was not significantly modulated. CONCLUSION : These results suggest that RVT attenuates MCT-induced pulmonary hypertension and it may represent a new strategy for the treatment of pulmonary hypertension.
